Pedro Ricardo Lowenstein

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. pmc A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics
    Mariana Puntel
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center UCLA, 8700 Beverly Blvd, Davis Building Research Pavilion, Room 5090, Los Angeles, CA 90048, USA
    J Virol 84:6007-17. 2010
  2. pmc In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain
    Carlos Barcia
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Exp Med 203:2095-107. 2006
  3. pmc T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury
    Carlos Barcia
    Board of Governors Gene Therapeutics Research Institute, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS ONE 3:e2977. 2008
  4. pmc Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses
    Pedro R Lowenstein
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, California 90048, USA
    Neurotherapeutics 4:715-24. 2007
  5. pmc Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions
    Pedro R Lowenstein
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90048, USA
    Curr Gene Ther 7:347-60. 2007
  6. ncbi request reprint Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects
    Pedro R Lowenstein
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Medicine, UCLA, Los Angeles, CA, USA
    Mol Ther 9:771-4. 2004
  7. pmc With a little help from my f(X)riends!: the basis of Ad5-mediated transduction of the liver revealed
    Pedro R Lowenstein
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, and Department of Pharmacology, University of California, Los Angeles, California 90048, USA
    Mol Ther 16:1004-6. 2008
  8. pmc Recent advances in the pharmacology of neurological gene therapy
    Pedro Ricardo Lowenstein
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center and Department of Medicine, University of California, Los Angeles, USA
    Curr Opin Pharmacol 4:91-7. 2004
  9. pmc Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?
    Pedro R Lowenstein
    Board of Governors Gene Therapeutics Research Institute, Department of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Curr Gene Ther 9:368-74. 2009
  10. ncbi request reprint Progress and challenges in viral vector-mediated gene transfer to the brain
    Pedro R Lowenstein
    Gene Therapeutics Research Institute, Department of Medicine, School of Medicine, University of California Los Angeles, 90048, USA
    Curr Opin Mol Ther 4:359-71. 2002

Research Grants

  1. Gene Therapy for Glioma
    Pedro Lowenstein; Fiscal Year: 2004
  2. Gene Therapy for Neurological Diseases
    Pedro Lowenstein; Fiscal Year: 2006

Collaborators

  • Maria Castro
  • Philip Ng
  • ROBERT PECHNICK
  • John R Ohlfest
  • G Elizabeth Pluhar
  • P F Moore
  • Carlos Barcia
  • Thomas Southgate
  • Jinwei Hu
  • Waldemar Debinski
  • M Weller
  • U Naumann
  • Antoni Ribas
  • MICHELE CALOS
  • Ronald Mandel
  • Katsuaki Sato
  • Antonia Follenzi
  • Marianela Candolfi
  • James F Curtin
  • Chunyan Liu
  • Mariana Puntel
  • Weidong Xiong
  • Kurt M Kroeger
  • Gwendalyn D King
  • A K M Ghulam Muhammad
  • Kader Yagiz
  • Donna Palmer
  • Jeffrey M Zirger
  • Daniel Larocque
  • Sonali Mondkar
  • Kurt Kroeger
  • A K M G Muhammad
  • Catherine Farrokhi
  • David Foulad
  • Jonathan Lerner
  • Andrew B Freese
  • Nicholas S R Sanderson
  • Sharon Lee
  • Jieping Yang
  • Matthew Tesarfreund
  • Yohei Mineharu
  • Niyati Bondale
  • John D Young
  • Josee Bergeron
  • W Stephen Nichols
  • Elizabeth A McNiel
  • Lali Medina-Kauwe
  • Hasmik Agadjanian
  • Shyam Goverdhana
  • Evelyn Abordo-Adesida
  • Oliver Dorigo
  • Alireza Biglari
  • Sumia Ali
  • Anne David
  • Andres Hurtado-Lorenzo
  • Daniel Stone
  • Ali Zadmehr
  • Niyati S Bondale
  • Ron Rodriguez
  • Dhruv Sareen
  • Dorothy Khan
  • Alireza Salem
  • Gabrielle E Ahlzadeh
  • Clare E Thomas
  • Kolja Wawrowsky
  • Clive N Svendsen
  • Randy Donelson
  • Mia Wibowo
  • Kevin C Reyes
  • Liliana M Lacayo
  • Julie Avalos
  • Joe Girton
  • Maksim Khayznikov
  • Moshe Arditi
  • Naiyou Liu
  • Katherine A Treuer
  • Begonya Comin-Anduix
  • Hikmat Assi
  • Nicholas S Sanderson
  • Matthew R Edwards
  • Mary C Clark
  • Nico Van Rooijen
  • Kathrin S Michelsen
  • Gabrielle E Alzadeh
  • Catherine J Bresee
  • Anderson Alden
  • A K M Muhammad
  • Matthew Edwards
  • Charlene M Manalo
  • Sarah B Honig

Detail Information

Publications43

  1. pmc A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics
    Mariana Puntel
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center UCLA, 8700 Beverly Blvd, Davis Building Research Pavilion, Room 5090, Los Angeles, CA 90048, USA
    J Virol 84:6007-17. 2010
    ....
  2. pmc In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain
    Carlos Barcia
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Exp Med 203:2095-107. 2006
    ..Herein, we demonstrate that the in vivo formation of SMAC at immunological synapses between effector CD8+ T cells and target cells precedes and mediates clearance of virally infected brain astrocytes...
  3. pmc T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury
    Carlos Barcia
    Board of Governors Gene Therapeutics Research Institute, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS ONE 3:e2977. 2008
    ..How target virally infected astrocytes respond to the formation of immunological synapses established by effector T cells is unknown...
  4. pmc Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses
    Pedro R Lowenstein
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, California 90048, USA
    Neurotherapeutics 4:715-24. 2007
    ....
  5. pmc Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions
    Pedro R Lowenstein
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90048, USA
    Curr Gene Ther 7:347-60. 2007
    ....
  6. ncbi request reprint Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects
    Pedro R Lowenstein
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Medicine, UCLA, Los Angeles, CA, USA
    Mol Ther 9:771-4. 2004
  7. pmc With a little help from my f(X)riends!: the basis of Ad5-mediated transduction of the liver revealed
    Pedro R Lowenstein
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, and Department of Pharmacology, University of California, Los Angeles, California 90048, USA
    Mol Ther 16:1004-6. 2008
  8. pmc Recent advances in the pharmacology of neurological gene therapy
    Pedro Ricardo Lowenstein
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center and Department of Medicine, University of California, Los Angeles, USA
    Curr Opin Pharmacol 4:91-7. 2004
    ....
  9. pmc Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?
    Pedro R Lowenstein
    Board of Governors Gene Therapeutics Research Institute, Department of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Curr Gene Ther 9:368-74. 2009
    ....
  10. ncbi request reprint Progress and challenges in viral vector-mediated gene transfer to the brain
    Pedro R Lowenstein
    Gene Therapeutics Research Institute, Department of Medicine, School of Medicine, University of California Los Angeles, 90048, USA
    Curr Opin Mol Ther 4:359-71. 2002
    ..Further improvements in viral vectors will facilitate clinical trials in the near future...
  11. ncbi request reprint Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective
    Pedro R Lowenstein
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Research Pavilion, Room 5093, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Trends Immunol 23:23-30. 2002
    ..Elucidating the cellular and molecular basis of these differential reactions is essential to the long-term success of neurological gene therapy...
  12. pmc Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model
    Gwendalyn D King
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Molecular and Medical Pharmacology, University of California Los Angeles 90048, USA
    Neuro Oncol 10:19-31. 2008
    ..05). Our results demonstrate that combination therapy with AdFlt3L and AdTK can eradicate multifocal brain tumor disease in a syngeneic, intracranial GBM model...
  13. pmc Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits
    Gwendalyn D King
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Ther 16:682-90. 2008
    ..These findings can serve to underpin further developments of this therapeutic modality, leading toward implementation of a Phase I clinical trial...
  14. pmc Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro
    Marianela Candolfi
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90069, USA
    Neuro Oncol 9:245-58. 2007
    ..HC-Ads encoding therapeutic transgenes under the control of regulatory sequences driven by the mCMV promoter are excellent vectors for the treatment of spontaneous GBM in dogs, which constitute an ideal preclinical animal model...
  15. pmc Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells
    Marianela Candolfi
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90048, USA
    Mol Ther 14:371-81. 2006
    ..We conclude that expression levels of adenoviral receptors do not predict their transduction efficiency or biological function...
  16. ncbi request reprint Use of recombinant adenovirus for gene transfer into the rat brain. Evaluation of gene transfer efficiency, toxicity, and inflammatory and immune reactions
    Andres Hurtado-Lorenzo
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Medicine, University of California Los Angeles UCLA, Los Angeles, CA, USA
    Methods Mol Med 76:113-33. 2003
  17. pmc Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells
    Oliver Dorigo
    Molecular Biology Institute, University of California at Los Angeles, 611 Charles E Young Dr East, Los Angeles, CA 90095 1570, USA
    J Virol 78:6556-66. 2004
    ..This novel gene transfer system has the potential to confer long-term episomal transgene expression and therefore to correct genetic defects with reduced vector-related toxicity and without insertional mutagenesis...
  18. pmc Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics
    Marianela Candolfi
    Gene Therapeutics Research Institute, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 107:20021-6. 2010
    ..These shortcomings were overcome by our therapeutic Ad, thus representing a significant advance in the development of targeted therapeutics for GBM...
  19. pmc Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses
    Evelyn Abordo-Adesida
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Hum Gene Ther 16:741-51. 2005
    ..A systemic immune response against vector components alone did not cause brain inflammation, possibly because vector-derived epitopes were not being presented in the CNS...
  20. pmc Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression
    A K M Ghulam Muhammad
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90048, USA
    Clin Cancer Res 15:6113-27. 2009
    ..Glioblastoma multiforme is a deadly primary brain cancer. Because the tumor kills due to recurrences, we tested the hypothesis that a new treatment would lead to immunological memory in a rat model of recurrent glioblastoma multiforme...
  21. pmc Adenoviral-mediated gene transfer into the canine brain in vivo
    Marianela Candolfi
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Neurosurgery 60:167-77; discussion 178. 2007
    ..We assayed the transduction efficiency of adenoviral vectors (Ads) encoding beta-galactosidase (betaGal), TK, and Flt3L in J3T dog GBM cells in vitro and in the dog brain in vivo...
  22. pmc High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity
    Gwendalyn D King
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd, Davis Bldg, Research Pavilion, Rm 5090, Los Angeles, CA 90048, USA
    J Virol 82:4680-4. 2008
    ..First-generation Ad-TK failed to elicit tumor regression in this model. These results pave the way for implementing HC-Ad-TK-mediated gene therapy as a powerful adjuvant for treating GBM...
  23. pmc Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors
    Jeffrey M Zirger
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, and Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Viral Immunol 19:508-17. 2006
    ....
  24. pmc Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain
    Weidong Xiong
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Ther 16:343-51. 2008
    ..This factor should be considered when developing gene therapies for neurological use...
  25. pmc Gene transfer into rat brain using adenoviral vectors
    Mariana Puntel
    Board of Governors Gene Therapeutics Research Institute, Departments of Medicine and Biomedical Sciences, Cedars Sinai Medical Center and Departments of Medicine, and Molecular and Medical Pharmacology, Jonsson Comprehensive Cancer Center, Brain Research Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Curr Protoc Neurosci . 2010
    ..Quantitation of adenoviral vector genomes within the rat brain using qPCR is also described...
  26. pmc Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders
    Pedro R Lowenstein
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Medicine, UCLA, Los Angeles, California 90048, USA
    Int Rev Neurobiol 55:3-64. 2003
  27. pmc HMGB1 mediates endogenous TLR2 activation and brain tumor regression
    James F Curtin
    Department of Medicine, Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS Med 6:e10. 2009
    ....
  28. pmc Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity
    Marianela Candolfi
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Medicine and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 15:4401-14. 2009
    ....
  29. pmc Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety
    Marianela Candolfi
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Curr Gene Ther 9:409-21. 2009
    ....
  30. pmc Gene transfer into neural cells in vitro using adenoviral vectors
    Thomas Southgate
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center and Department of Medicine, University of California at Los Angeles, California, USA
    Curr Protoc Neurosci . 2008
    ....
  31. pmc Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators
    James F Curtin
    The Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center and Department of Molecular, Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Methods Mol Biol 434:239-66. 2008
    ....
  32. pmc Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials
    James F Curtin
    Department of Biomedical Sciences, Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS ONE 3:e1983. 2008
    ..Clinical trials that combine Treg depletion with tumor vaccination are underway to determine whether transient Treg depletion can enhance anti-tumor immune responses and improve long term survival in cancer patients...
  33. pmc Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression
    Sumia Ali
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90048, USA
    Mol Ther 10:1071-84. 2004
    ..Our results have profound implications for immune-mediated brain tumor therapy and also suggest the ability to recruit DC-like cells within the brain parenchyma in response to the local expression of Flt3L from adenoviral vectors...
  34. pmc Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression
    Marianela Candolfi
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    J Neurooncol 85:133-48. 2007
    ..Importantly, our results indicate that dog GBM emerges as an attractive animal model for testing novel therapies in a spontaneous tumor in the context of a larger brain...
  35. pmc Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial
    Weidong Xiong
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center and Department of Medicine and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    PLoS ONE 5:e11074. 2010
    ....
  36. pmc Gene therapy and targeted toxins for glioma
    Gwendalyn D King
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Curr Gene Ther 5:535-57. 2005
    ..Once this is addressed, and we develop effective gene therapies in models that better replicate the clinical scenario, gene therapy will provide a powerful approach to treat and manage brain tumors...
  37. pmc Rapid upregulation of interferon-regulated and chemokine mRNAs upon injection of 108 international units, but not lower doses, of adenoviral vectors into the brain
    Jeffrey M Zirger
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    J Virol 80:5655-9. 2006
    ..This indicates the presence of a threshold dosage of adenovirus needed to elicit an acute innate inflammatory response...
  38. pmc Combining cytotoxic and immune-mediated gene therapy to treat brain tumors
    James F Curtin
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Research Pavilion, Suite 5090, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Curr Top Med Chem 5:1151-70. 2005
    ..We have therefore reviewed the most exciting non-invasive, in vivo imaging techniques which can be used in combination with gene therapy to monitor therapeutic efficacy over time...
  39. pmc Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model
    Alireza Biglari
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Research Pavilion, Suite 5090, 8700 Beverly Boulevard, Los Angeles, California 90048, USA
    Cancer Gene Ther 11:721-32. 2004
    ....
  40. pmc Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses
    Weidong Xiong
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd, Davis Building, Research Pavilion, Room 5090, Los Angeles, CA 90048, USA
    J Virol 80:27-37. 2006
    ..Therefore, these vectors display two coveted characteristics of clinically useful vectors, namely their regulation and effectiveness even in the presence of prior immunization against adenovirus...
  41. pmc One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications
    Carlos Barcia
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Ther 15:2154-63. 2007
    ..This study therefore indicates the utility of HC-Adv as a powerful gene therapy vector for chronic neurological disorders, even in patients who had been pre-exposed to Ad prior to gene therapy...
  42. pmc Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression
    Daniel Stone
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Research Pavilion, Suite 5090, 8700 Beverly Boulevard, Los Angeles, California 90048, USA
    Mol Ther 8:400-11. 2003
    ..Taken together these data demonstrate a role for NF-kappaB and IL-1 in immune system-mediated elimination of Ad-mediated CNS transgene expression...
  43. pmc Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology
    Daniel Larocque
    Gene Therapeutics Research Institute, Cedars Sinai Biomedical Sciences Graduate Program, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 107:14443-8. 2010
    ....

Research Grants2

  1. Gene Therapy for Glioma
    Pedro Lowenstein; Fiscal Year: 2004
    ..Our long term aim is to translate this novel therapeutic approach into a Phase I clinical trial for GBM. ..
  2. Gene Therapy for Neurological Diseases
    Pedro Lowenstein; Fiscal Year: 2006
    ..abstract_text> ..